Nuvectis Pharma (NVCT) Treasury Shares (2023 - 2026)

Nuvectis Pharma has disclosed Treasury Shares across 4 years of filings, most recently posting $2.9 million for Q1 2026.

• Treasury Shares for Q1 2026 came in at $2.9 million, up 36.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.9 million (up 36.55% YoY), and the FY2025 annual result was $2.2 million, up 63.03% from the prior year.
• Treasury Shares came in at $2.9 million for Q1 2026 at Nuvectis Pharma, up from $2.2 million in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $2.9 million in Q1 2026 to a low of $941496.0 in Q4 2023.
• The 4-year median for Treasury Shares is $2.1 million (2025), against an average of $1.9 million.
• Across the five-year window, Treasury Shares surged 63.03% in 2025 and jumped 36.55% in 2026, its largest moves.
• Nuvectis Pharma's Treasury Shares stood at $941496.0 in 2023, then soared by 45.06% to $1.4 million in 2024, then soared by 63.03% to $2.2 million in 2025, then advanced by 29.54% to $2.9 million in 2026.
• The last three Treasury Shares figures came in at $2.9 million (Q1 2026), $2.2 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.